For more than 10 years, dual antiplatelet therapy with aspirin and clopidogrel has remained
the cornerstone of treatment for patients with acute coronary syndrome (ACS). The novel …

Platelets are increasingly being recognized for playing roles beyond thrombosis and
hemostasis. Today we know that they mediate inflammation by direct interactions with innate …

Abstract Aim The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management
of Patients With Chronic Coronary Disease” provides an update to and consolidates new …

Guidelines, Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dual antiplatelet therapy, Acute
coronary syndromes, Coronary artery bypass grafting, Coronary artery disease, Drug-eluting …

Background The potential benefit of dual antiplatelet therapy beyond 1 year after a
myocardial infarction has not been established. We investigated the efficacy and safety of …

Surveys and registries are needed to verify that real-life daily practice is in keeping with what
is recommended in the guidelines, thus completing the loop between clinical research …

Background: Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after
acute coronary syndrome (ACS) when added to statin therapy. After ACS, patients vary …

Background: Patients with stable ischemic heart disease and previous myocardial infarction
(MI) vary in their risk for recurrent cardiovascular events. Atherothrombotic risk assessment …

Racial differences in the pathophysiology of atherothrombosis are poorly understood. We
explored the function and transcriptome of platelets in healthy black (n= 70) and white (n …

Ischemic stroke is among the leading causes of disability and death worldwide. In acute
ischemic stroke, the rapid recanalization of occluded cranial vessels is the primary …